After early findings (in the 1970s and 1980s) that acetylcholinesterase inhibitors could slow the progression of memory loss in patients with AD [94,95,96,98,99,100], this became the most used anti-AD class of drugs to this day, despite these drugs not being disease-modifying and potentially producing severe and uncomfortable side effects [100]. This evidence concerns the gene ACHE and Alzheimer disease.